IBRX R&D to Revenue
Immunitybio Inc · R&D to Revenue
IBRX R&D to Revenue
Latest reported183.49%period ending
IBRX FY R&D/Revenue (74.33% → 183.49%)
Latest values, visible window
High-resolution chart · PNG
IBRX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 183.4925% | |
| 1,289.549% | |
| 37,357.8778% | |
| 103,395.4167% | |
| 20,980.5139% | |
| 23,059.0083% | |
| 113,686.0465% | |
| 113,655.3191% | |
| 88,395.5556% | |
| 60,331.8182% | |
| 4,844.9153% | |
| 248.83% | |
| 74.3333% |